메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders

SHANGHAI and OAKLAND, Calif., Sept. 17, 2025 -- Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Aditum Bio will provide funding for Kalexo Bio, and the parties will collaborate to advance 2MW7141 into clinical development. Kalexo Bio was founded by Aditu
- 김갑성 기자
- 2025-09-17 20:00
Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9)

EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its subsidiary, Alteogen Biologics. EYLUXVI® is Alteogen's second approved biosimilar, following the approval of the Herceptin® biosimilar, further expanding Alteogen's biosimi
- 김갑성 기자
- 2025-09-17 15:40
"EchoCare" Ultrasound Large Model Launched in Hong Kong as CAIR Showcases Large-Scale Ultrasound Dataset Training Achievements

HONG KONG, Sept. 17, 2025 -- Amid the global surge in rapid advancements in artificial intelligence, the healthcare sector is entering a critical phase of intelligent transformation. As a vital tool in clinical diagnosis, ultrasound imaging has long been plagued by issues such as low efficiency, inconsistent diagnostic standards, and insufficient AI model accuracy. These challenges urgently call for technological breakthroughs and industrial collaboration. Against this backdrop, Centre for Artificial Intelligence and Robotics (CAIR), Hong Kong Institute of Science & Innovation (HKISI), Ch
- 김갑성 기자
- 2025-09-17 13:32
Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

WUXI, China, Sept. 17, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK). This marks the first GMP inspection conducted by Turkey's TITCK at WuXi Biologics. Achieving the certification underscores the company's commitment to upholding stringent international quality standards across its global network. During the five-day onsite inspection
- 김갑성 기자
- 2025-09-17 12:00
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF

SHENZHEN, China, Sept. 17, 2025 -- Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (DMF) registration with the U.S. FDA. Exosomes, as a next-generation bioactive carrier, boast unique advantages such as low immunogenicity, strong tissue penetration, and potential for targeted modification, offering immense promise for medical applications. However, the technical barriers and research challenges in Exosome development place them at the forefront of complexity among bioact
- 김갑성 기자
- 2025-09-17 10:30
Malaysia Healthcare Week Debuts in Kuwait, Strengthening Malaysia-Kuwait Medical Partnership

[ 메디채널 김갑성 기자 ] Spearheaded by the Malaysia Healthcare Travel Council, the event builds momentum towards the Malaysia Year of Medical Tourism 2026. KUWAIT CITY, Kuwait, Sept. 17, 2025 -- Building on Malaysia's established reputation as a premier global healthcare destination and as part of the strategic lead-up to the Malaysia Year of Medical Tourism 2026 (MYMT2026), Malaysia Healthcare Travel Council (MHTC), together with the Embassy of Malaysia in Kuwait and REXPOCentral Sdn Bhd, launched Malaysia Healthcare Week in Kuwait. This landmark initiative showcases Malaysia's world-class
- 김갑성 기자
- 2025-09-17 10:01
From Sky-High Luxury to Stair-High Challenge: China World Summit Wing, Beijing Elevates Its Urban Lifestyle Destination Positioning with the Return of Vertical Run

BEIJING, Sept. 17, 2025 -- The 2025 China World Summit Wing, Beijing Vertical Run powered to a perfect finish on September 13, 2025 as 1000+ runners conquered 330 meters, 80 floors and over 2,000 steps at the heart of Beijing. Rising above the capital's vibrant CBD, China World Summit Wing, Beijing is Beijing's definitive Urban Lifestyle Destination, curating immersive stay, dining and wellness experiences that embraces life enrichment while inspiring people to live holistically, actively and sustainably. As part of the Shangri-La Group, we identify with our group's global 'Trip
- 황정호 기자
- 2025-09-17 09:41
Tapping Into the Trillion-Dollar Healthcare Market: Home Control(1747.HK) will Establish Hong Kong Subsidiary and Build a Global Health Services Ecosystem

HONG KONG, Sept. 17, 2025 -- Home Control (1747.HK), one of the most closely watched small-cap names on the Hong Kong market this year, has once again caught investors' attention. After a tenfold rally in the first half of 2025, the Company has unveiled a series of bold strategic moves: pursuing dual growth engines in smart home control and home healthcare and reinforcing its board with high-profile figures in smart healthcare, Web3, fintech, and ESG. Most notably, on September 12, the Company announced the establishment of a wholly owned subsidiary in Hong Kong to spearhead its healthcare ex
- 김갑성 기자
- 2025-09-17 08:00
Genesis MedTech J-VALVE® TF Approved by NMPA, China's First Transfemoral TAVR for Aortic Regurgitation

[ 메디채널 김갑성 기자 ] Clinical data demonstrate low mortality, fewer complications and faster patient recovery with a minimally invasive alternative to open-heart surgery SINGAPORE, Sept. 17, 2025 -- Genesis MedTech's structural heart subsidiary, Suzhou Jiecheng, has received approval from China's National Medical Products Administration (NMPA) for the J-VALVE® Transfemoral Transcatheter Aortic Valve Replacement (TAVR) System (J-VALVE TF), the first transfemoral TAVR system approved in China for the treatment of aortic regurgitation. Aortic regurgitation is a progressive and pot
- 김갑성 기자
- 2025-09-17 07:30
Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

- ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. - ASC30 tablet's higher efficacy is supported by its higher oral drug exposures. - ASC30 is safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs). There was no vomiting incidence in multiple ascending dose (MAD) cohort 1 due to 2 mg to 5 mg weekly titration strategy. HONG KONG, Sept. 17, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that resul
- 김갑성 기자
- 2025-09-17 07:30

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-17_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 17일 22시 00분